News
CDTX
0.7222
-1.07%
-0.0078
CIDARA THERAPEUTICS- ISSUED FINANCIAL STATEMENTS FOR FY ENDED DEC 31, 2021, 2022 ON FORM 10-K FOR FY ENDED DEC 31, 2022 NOT TO BE BE RELIED ON
Reuters · 1d ago
CIDARA THERAPEUTICS INC - IDENTIFIED A MATERIAL WEAKNESS IN INTERNAL CONTROL OVER FINANCIAL REPORTING
Reuters · 1d ago
Weekly Report: what happened at CDTX last week (0408-0412)?
Weekly Report · 2d ago
Cidara Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 04/08 18:30
Cidara Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/08 18:30
Buy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program Developments
TipRanks · 04/08 14:45
Weekly Report: what happened at CDTX last week (0401-0405)?
Weekly Report · 04/08 10:26
Cidara Therapeutics Presents Promising New Data On Novel Drug-Fc Conjugate Candidates At The AACR Annual Meeting 2024
Cidara Therapeutics will deliver four poster presentations at the American Association for Cancer Research Annual Meeting in San Diego, 2024. The company's CD73/PD-1 drug Fc-conjugate demonstrates improved tumor reduction compared to PD-1 monotherapy. CCR5-targeting DFC demonstrates potent efficacy in a colorectal cancer mouse model. Cidara is a biotechnology company developing drug-Fc conjugate immunotherapies.
Benzinga · 04/05 19:15
CIDARA THERAPEUTICS INC - CCR5-TARGETING DFC DEMONSTRATES POTENT EFFICACY IN COLORECTAL CANCER MOUSE MODEL
Reuters · 04/05 19:00
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
Barchart · 04/05 14:00
SLS, IBIO and ALDX are among premarket gainers
On the Move SLS, IBIO and ALDX are among premarket gainers. ARCA biopharma +91% to merge with Oruka Therapeutics in all-stock transaction. Vanda Pharmaceuticals +26% stock jumps as FDA approves Fanapt tablets for bipolar disorder.
Seeking Alpha · 04/03 12:53
CIDARA THERAPEUTICS: SEES SIGNIFICANT CHANGES IN CO’S RESULTS OF OPERATIONS FOR YEAR ENDED DEC 31, 2023 COMPARED TO YEAR ENDED DEC 31, 2022
Reuters · 04/01 12:11
CIDARA THERAPEUTICS: CHANGES IN RESULTS OF OPERATIONS FOR YEAR ENDED DEC 31, 2023 EXPECTED DUE TO ANTICIPATED MATERIAL CHANGE IN LOSS FROM OPERATIONS
Reuters · 04/01 12:11
CIDARA THERAPEUTICS INC FILES FOR NON-TIMELY 10-K WITH US SEC - SEC FILING
Reuters · 04/01 12:11
Weekly Report: what happened at CDTX last week (0325-0329)?
Weekly Report · 04/01 10:25
Weekly Report: what happened at CDTX last week (0318-0322)?
Weekly Report · 03/25 10:28
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/21 21:30
Weekly Report: what happened at CDTX last week (0311-0315)?
Weekly Report · 03/18 10:26
Weekly Report: what happened at CDTX last week (0304-0308)?
Weekly Report · 03/11 10:24
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/06 22:55
More
Webull provides a variety of real-time CDTX stock news. You can receive the latest news about Cidara Theraptcs through multiple platforms. This information may help you make smarter investment decisions.
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.